Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis

Lisa-Ann Fraser1 Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, CanadaCorrespondence[email protected]

Kelly N Vogt1 Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada

Jonathan D Adachi2 Department of Medicine, McMaster University, Hamilton, Ontario, Canada

Lehana Thabane1 Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada

Pages 157-166 | Published online: 09 May 2011

Cite this article

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

HanleyDAJosseRGPrevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada: 1. IntroductionCMAJ199615579219338837540
PubMed Web of Science ®Google Scholar
EbelingPRClinical practice. Osteoporosis in menN Engl J Med2008358141474148218385499
PubMed Web of Science ®Google Scholar
BrownJPJosseRGScientific Advisory Council of the Osteoporosis Society of Canada. Clinical practice guidelines for the diagnosis and management of osteoporosis in CanadaCMAJ200216710 Suppl134
PubMed Web of Science ®Google Scholar
DelmasPDTreatment of postmenopausal osteoporosisLancet200235993222018202612076571
PubMed Web of Science ®Google Scholar
CranneyAWellsGWillanAMeta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal womenEndocr Rev200223450851612202465
PubMed Web of Science ®Google Scholar
PapapoulosSEBisphosphonates for postmenopausal osteoporosisPrimer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism7th edRosenCJWashingtonASBMR2008237
Google Scholar
OttSMLong-term safety of bisphosphonatesJ Clin Endocrinol Metab20059031897189915758064
PubMed Web of Science ®Google Scholar
ShebbaAOsteoporosis: how long should we treat?Curr Opin Endocrinol Diabetes Obs2008156502507
PubMedGoogle Scholar
NeviaserASLaneJMLenartBALow-energy femoral shaft fractures associated with alendronate useJ Ortho Trauma2008225346350
Web of Science ®Google Scholar
OdvinaCVZerwekhJERaoDSSeverely suppressed bone turnover; a potential complication of alendronate therapyJ Clin Endocrinol Metab20059031294130115598694
PubMed Web of Science ®Google Scholar
GoddardMSReidKRJohnstonJCKhanujaHSAtraumatic bilateral femur fracture in long-term bisphosphonate useOrthopedics2009328piiorthosupersite.com/view.asp?rID=4193310.3928/01477447-20090624-27.19708622
PubMedGoogle Scholar
KhanAASandorGKDoreEBisphosphonate associated osteonecrosis of the jawJ Rheumatol200936347850919286860
PubMed Web of Science ®Google Scholar
LokeYKJeevananthamVSinghSBisphosphonates and atrial fibrillation: systematic review and meta-analysisDrug Saf200932321922819338379
PubMed Web of Science ®Google Scholar
HaleemSLutchmanLMayahiRMortality following hip fracture: trends and geographical variations over the last 40 yearsInjury200839101157116318653186
PubMed Web of Science ®Google Scholar
BentlerSELiuLObrizanMThe aftermath of hip fracture: discharge placement, functional status change, and mortalityAm J Epidemiol2009170101290129919808632
PubMed Web of Science ®Google Scholar
HigginsJPTGreenSThe Cochrane CollaborationCochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. http://www.cochrane-handbook.org. Accessed March 30, 2011
Google Scholar
BlackDMSchwartzAVEnsrudKEEffects of continuing or stopping alendronate after 5 years of treatment. The fracture intervention trial long-term extension (FLEX): a randomized trialJAMA2006296242927293817190893
PubMed Web of Science ®Google Scholar
MillerPDWattsNBLicataAACyclical etidronate in the treatment of postmenopausal osteoporosis: Efficacy and safety after seven years of treatmentAm J Med199710364684769428829
PubMed Web of Science ®Google Scholar
BoneHGHoskingDDevogelaerJPTen years’ experience with alendronate for osteoporosis in postmenopausal womenN Engl J Med2004350121189119915028823
PubMed Web of Science ®Google Scholar
ToninoRPMeunierPJEmkeyRSkeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic womenJ Clin Endocrinol Metab20008593109311510999794
PubMed Web of Science ®Google Scholar
BlackDMCummingsSRKarpfDBRandomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research GroupLancet19963489041153515418950879
PubMed Web of Science ®Google Scholar
WattsNBDiabDLLong-term use of bisphosphonates in osteoporosisJ Clin Endocrinol Metab20109541555156520173017
PubMed Web of Science ®Google Scholar
BaggerYZTankoLBAlexandersenPAlendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawalBone200333330130713678770
PubMed Web of Science ®Google Scholar
CurtisJRWestfallAOChengHRisk of hip fracture after bisphosphonate discontinuation: implications for a drug holidayOsteoporos Int200819111613162018483689
PubMed Web of Science ®Google Scholar
CooperCBeyond daily dosing: clinical experienceBone2006384 Suppl 1S13S1716520105
PubMed Web of Science ®Google Scholar
GeusensPBisphosphonates for postmenopausal osteoporosis: determining duration of treatmentCurr Osteoporos Rep200971121719239824
PubMedGoogle Scholar
BriotKTremollieresFThomasTRouxCHow long should patients take medications for postmenopausal osteoporosis?Joint Bone Spine2007741243117223374
PubMed Web of Science ®Google Scholar
RosenCJBrownSAA rational approach to evidence gaps in the management of osteoporosisAm J Med2005118111183118916271898
PubMed Web of Science ®Google Scholar
LarocheMTreatment of osteoporosis: all the questions we still cannot answerAm J Med2008121974474718724959
PubMed Web of Science ®Google Scholar

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date